AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28753230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings with call-in number for colonoscopy and mailed fecal tests (arm 2)
Number of subjects: 4675
Study 28753230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings plus brief telephone assistance (arm 3)
Number of subjects: 4675
Study 28753230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings and assistance plus nurse navigation (arm 4)
Number of subjects: 4675
Study 26141683 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-cetuximab followed by oxaliplatin-based second-line chemotherapy with bevacizumab (Arm A)
Number of subjects: 500
Study 26141683 — intervention group
Group type: COMPARATOR
Intervention: OPTIMOX-bevacizumab followed by irinotecan-based second-line chemotherapy with bevacizumab and anti-EGFR monoclonal antibody (Arm B)
Number of subjects: 500
Study 23218563 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 383
Study 23218563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 21139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaginal microbicide gel containing cellulose acetate 1,2‐benzenedicarboxylate in a glycerol‐based vehicle
Number of subjects: 5
Study 21139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate vaginal microbicide gel
Number of subjects: 5
Study 18417521 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid polymerase chain reaction based screening test for MRSA
Number of subjects: 6888
Study 18417521 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture
Number of subjects: 6888
Study 16832124 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (antibiotics) administered on the day before and the day of embryo transfer
Number of subjects: 350
Study 16832124 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 350
Study 12510037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary-artery catheter
Number of subjects: 1994
Study 12510037 — intervention group
Group type: COMPARATOR
Intervention: Standard care without pulmonary-artery catheter
Number of subjects: 1994
Study 12510037 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1994
Study 12510037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1994
Study 10750134 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 204
Study 10750134 — intervention group
Group type: COMPARATOR
Intervention: No ICD (Control)
Number of subjects: 204
Study 8900553 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (50 mg per m2) + Misoprostol (800 micrograms)
Number of subjects: 282
Study 8900553 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms)
Number of subjects: 282
Study 8900553 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (vaginal administration)
Number of subjects: 282
Study 8900553 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedure satisfaction
Number of subjects: 282
Study 8900553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring
Number of subjects: 282
Study 1797509 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and Glyburide (IG)
Number of subjects: 20
Study 1797509 — intervention group
Group type: COMPARATOR
Intervention: Insulin and Placebo (IP)
Number of subjects: 20
Study 7005630 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 24
Study 7005630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 7005630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30741856 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal supervision (SUP)
Number of subjects: 85
Study 30741856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpersonal supervision (NPS)
Number of subjects: 85
Study 30741856 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised control (CON)
Number of subjects: 85
Study 31679347 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment program
Number of subjects: 0
Study 31679347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis response plan
Number of subjects: 97
Study 28142085 — intervention group
Group type: COMPARATOR
Intervention: Contract for safety
Number of subjects: 97
Study 28142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisis response planning
Number of subjects: 97
Study 25841177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control training (CCT), consisting of 10 online training sessions.
Number of subjects: 0
Study 25841177 — intervention group
Group type: COMPARATOR
Intervention: Active control condition, consisting of 10 online training sessions.
Number of subjects: 0
Study 24106896 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus dexamethasone
Number of subjects: 1411
Study 24106896 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron/granisetron plus dexamethasone
Number of subjects: 1411
Study 21390173 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (80 µg/kg/min)
Number of subjects: 90
Study 21390173 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (saline control)
Number of subjects: 90
Study 21390173 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (saline control)
Number of subjects: 90
Study 19433134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (combined mechanical vibrations, continuous passive motion, and thermotherapy)
Number of subjects: 71
Study 19433134 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 71
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 0.5W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 1.0W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 0.5W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 1.0W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 1.5W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation without water (NW) group with 2.0W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 1.5W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation in water (IW) group with 2.0W power output
Number of subjects: 65
Study 17970683 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 65
Study 15471073 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa therapy with 15 microg of diluted buserelin acetate given once a day intranasally
Number of subjects: 59
Study 15471073 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg daily by oral administration
Number of subjects: 59
Study 11327741 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCTs) infusion
Number of subjects: 9
Study 11327741 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs) in a 1:1 mixture with LCTs
Number of subjects: 9
Study 9649466 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus prazosin
Number of subjects: 56
Study 9649466 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus ISMN
Number of subjects: 56
Study 8189403 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (mental arithmetic)
Number of subjects: 20
Study 8189403 — intervention group
Group type: COMPARATOR
Intervention: No stress condition (30-min initial baseline only)
Number of subjects: 20
Study 2511584 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized physician prompts for mammography referral, reminder postcards for scheduled appointments, telephone calls to encourage rescheduling of missed appointments.
Number of subjects: 0
Study 2511584 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of out-of-pocket mammography expenses at three of the five sites.
Number of subjects: 0
Study 2511584 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated system of interventions (computer prompts, reduced expenses, appointment reminders).
Number of subjects: 0
Study 1064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid antacid co-administered with ferrous salts (carbonate, fumarate, sulphate)
Number of subjects: 0
Study 1064903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous carbonate with liquid antacid
Number of subjects: 0
Study 31486766 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial transposases
Number of subjects: 112
Study 31486766 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter bacterial transposases
Number of subjects: 112
Study 31486766 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer bacterial transposases
Number of subjects: 112
Study 31486766 — intervention group
Group type: EXPERIMENTAL
Intervention: Archaeal transposases
Number of subjects: 112
Study 29049382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based unannounced pill counts in START (Lesotho)
Number of subjects: 0
Study 29049382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-based unannounced pill counts in ENRICH (Ethiopia)
Number of subjects: 0
Study 26614138 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2mg/kg + Propofol
Number of subjects: 105
Study 26614138 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.3mg/kg + Propofol
Number of subjects: 105
Study 26614138 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Control Group)
Number of subjects: 105
Study 24063098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 5 mg/kg
Number of subjects: 30
Study 24063098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 10 mg/kg
Number of subjects: 30
Study 24063098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 15 mg/kg
Number of subjects: 30
Study 24063098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 100 mg/kg
Number of subjects: 30
Study 24063098 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 22047561 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial disease-management programs using nurse-based call centers
Number of subjects: 242417
Study 22047561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 242417
Study 19095850 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive heating under-patient blanket
Number of subjects: 56
Study 19095850 — intervention group
Group type: COMPARATOR
Intervention: Forced-air warming system
Number of subjects: 56
Study 17313906 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure centre-based exercise programme
Number of subjects: 943
Study 17313906 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led walking programme
Number of subjects: 943
Study 17313906 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 943
Study 15160265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine at 20 mg/day for 12 weeks
Number of subjects: 10
Study 11606923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole cream
Number of subjects: 72
Study 11606923 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% metronidazole cream
Number of subjects: 72
Study 11606923 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 72
Study 9602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study 9602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 80
Study 9602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with nitrous oxide
Number of subjects: 80
Study 9602580 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane with nitrous oxide
Number of subjects: 80
Study 7977476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 18
Study 7977476 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line ST-segment monitoring with sestamibi injection
Number of subjects: 18
Study 7977476 — intervention group
Group type: EXPERIMENTAL
Intervention: Predialysis imaging
Number of subjects: 18
Study 7977476 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment monitoring
Number of subjects: 18
Study 2485616 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 26
Study 2485616 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 26
Study 2485616 — intervention group
Group type: EXPERIMENTAL
Intervention: pernazine
Number of subjects: 26
Study 238548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 3 mg
Number of subjects: 69
Study 238548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 5 mg
Number of subjects: 69
Study 238548 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 69
Study 238548 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 69
Study 238548 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbitone 50 mg
Number of subjects: 69
Study 238548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30079756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 322
Study 30079756 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 322
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR)
Number of subjects: 200
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 200
Study 29369450 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohorts (baseline pain and PPT levels)
Number of subjects: 200
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PPTs
Number of subjects: 200
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of painful sites
Number of subjects: 200
Study 29369450 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 200
Study 27064060 — intervention group
Group type: EXPERIMENTAL
Intervention: R.A.P.I.D. system
Number of subjects: 100
Study 27064060 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Meditech (EM)
Number of subjects: 100
Study 27064060 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Orchard (EO)
Number of subjects: 100
Study 24484547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lo‐AscA (50 mg/kg/24 h, n = 8)
Number of subjects: 24
Study 24484547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi‐AscA (200 mg/kg/24 h, n = 8)
Number of subjects: 24
Study 24484547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose/water, n = 8)
Number of subjects: 24
Study 22205317 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN) providing 130-150% of resting energy expenditure (REE)
Number of subjects: 26
Study 22205317 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated parenteral nutrition (PN) matched to measured REE
Number of subjects: 26
Study 22205317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both standard and titrated PN regimens
Number of subjects: 26
Study 20807343 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 7.5 mg
Number of subjects: 106
Study 20807343 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate 40 mg
Number of subjects: 106
Study 20807343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 106
Study 17200359 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel followed by FEC chemotherapy with concurrent trastuzumab for 24 weeks
Number of subjects: 42
Study 17200359 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 42
Study 17200359 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 42
Study 17200359 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and trastuzumab
Number of subjects: 42
Study 15660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-control treatment strategy
Number of subjects: 716
Study 15660042 — intervention group
Group type: COMPARATOR
Intervention: Rhythm-control treatment strategy
Number of subjects: 716
Study 15660042 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 716
Study 15660042 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 716
Study 12407485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 300 mg QD
Number of subjects: 89
Study 12407485 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 150 mg BID
Number of subjects: 89
Study 10207493 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of hyoscyamine butylbromide
Number of subjects: 50
Study 10207493 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyoscyamine butylbromide)
Number of subjects: 50
Study 8527351 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem CD 180 mg
Number of subjects: 111
Study 8527351 — intervention group
Group type: COMPARATOR
Intervention: diltiazem SR 90 mg bid
Number of subjects: 111
Study 8527351 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem CD
Number of subjects: 111
Study 8527351 — intervention group
Group type: COMPARATOR
Intervention: diltiazem SR
Number of subjects: 111
Study 2695861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 100
Study 2695861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2695861 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 100
Study 1137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management for the initial 4 days in major hyphemas
Number of subjects: 0
Study 1137285 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0
Study 31521666 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month intervention including training of patients and their primary care physicians in evidence-based post-sepsis care, case management by trained nurses, and clinical decision support for PCPs.
Number of subjects: 291
Study 31521666 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by primary care physicians (PCPs).
Number of subjects: 291
Study 30698247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Knowledge Scale (DKN‐A)
Number of subjects: 202
Study 30698247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Attitudes Questionnaire (ATT‐19)
Number of subjects: 202
Study 30698247 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone (protective factor)
Number of subjects: 202
Study 30698247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education (risk factor)
Number of subjects: 202
Study 28464014 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural 200 mg MgSO4 added to 0.25% ropivacaine
Number of subjects: 70
Study 28464014 — intervention group
Group type: COMPARATOR
Intervention: 0.25% ropivacaine alone
Number of subjects: 70
Study 28464014 — intervention group
Group type: COMPARATOR
Intervention: 0.375% ropivacaine alone
Number of subjects: 70
Study 24595550 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100 (15 g/day, three times a day)
Number of subjects: 231
Study 24595550 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 231
Study 24595550 — intervention group
Group type: EXPERIMENTAL
Intervention: TU-100
Number of subjects: 231
Study 23780504 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of lansoprazole 30 mg
Number of subjects: 156
Study 23780504 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of lansoprazole 30 mg
Number of subjects: 156
Study 20945151 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-trained girls during cycle exercise
Number of subjects: 16
Study 20945151 — intervention group
Group type: COMPARATOR
Intervention: Untrained girls during cycle exercise
Number of subjects: 16
Study 20945151 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim-trained girls during upper body exercise
Number of subjects: 16
Study 20945151 — intervention group
Group type: COMPARATOR
Intervention: Untrained girls during upper body exercise
Number of subjects: 16
Study 18056225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg)
Number of subjects: 304
Study 18056225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 16439444 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg (IFX/IFX)
Number of subjects: 104
Study 16439444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO/IFX)
Number of subjects: 104
Study 12542586 — intervention group
Group type: EXPERIMENTAL
Intervention: Take‐home Diabetes Record (THDR)
Number of subjects: 127
Study 12542586 — intervention group
Group type: COMPARATOR
Intervention: Control group (no THDR)
Number of subjects: 127
Study 10968529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy immediately following cast removal
Number of subjects: 0
Study 10968529 — intervention group
Group type: COMPARATOR
Intervention: No active therapy following cast removal
Number of subjects: 0
Study 9578428 — intervention group
Group type: COMPARATOR
Intervention: Vaccination with ganglioside GM2 vaccine (GM2-KLH/QS-21)
Number of subjects: 2000
Study 9578428 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy with high or low intermediate doses of IFN-alpha2b (10 MU subcutaneously every day, 5 days per week for 4 weeks, followed by either 10 MU subcutaneously, three times weekly for 1 year, or 5 MU subcutaneously, three times weekly for 2 years)
Number of subjects: 2000
Study 8473717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for 6 weeks
Number of subjects: 23